

4-(3*H*-indol-2-ylamino)-2-(4-hydroxypiperidin-1-yl)pyrido[4,3-*d*]pyrimidin-5(6*H*)-one; and

2-(4-hydroxypiperidin-1-yl)-4-(4-phenoxyphenylamino)-8-phenylpyrido[4,3-*d*]pyrimidin-5(6*H*)-one;

or a pharmaceutically acceptable salt thereof.

57. A pharmaceutical formulation comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.
- ~~58. A method of treating a protein kinase mediated disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein said protein kinase mediated disease is selected from the group of consisting of psoriasis, rheumatoid arthritis, lymphoma, osteosarcoma, melanoma, breast cancer, renal cancer, prostate cancer, colorectal cancer, thyroid cancer, ovarian cancer, pancreatic cancer, neuronal cancer, lung cancer, uterine cancer, and gastrointestinal cancer.~~
- ~~59. The method of Claim 59, wherein said compound of Claim 1 is administered singly or in combination with one or more additional therapeutic agents.~~
- ~~60. The method of Claim 60, wherein said compound or salt is administered via intravenous administration, subcutaneous administration, inhalation, oral administration, rectal administration, parenteral, intravitreal administration, intramuscular administration, intranasal administration, dermal administration, topical administration, otic administration, ophthalmic administration, buccal administration, tracheal administration, bronchial administration, or sublingual administration.~~
- ~~61. A method of inhibiting growth of cancer cells, comprising contacting the cancer cells with a compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein the cancer cells are cells from a cancer selected from~~

~~acute lymphoblastic leukemia, acute promyelocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, lung cancer, colon cancer, brain cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, or breast cancer.~~

62. — ~~A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein said cancer is acute lymphoblastic leukemia, acute promyelocytic leukemia, chronic myelogenous leukemia, lung cancer, colon cancer, brain cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, or breast cancer.~~

63. — ~~The method of claim 64, wherein said compound is selected from the group consisting of:~~

~~2-(4-hydroxypiperidin-1-yl)-4-(3-(trifluoromethyl)phenylamino)pyrido[4,3-*d*]pyrimidine-5(6*H*)-one;~~

~~(*S*)-2-(pyrrolidin-3-ylamino)-4-(4-trifluoromethylamino)pyrido[4,3-*d*]pyrimidin-5(6*H*)-one;~~

~~(*S*)-4-(4-morpholinophenylamino)-2-(pyrrolidin-3-ylamino)pyrido[4,3-*d*]pyrimidin-5(6*H*)-one hydrochloride;~~

~~2-(4-(hydroxymethyl)piperidin-1-yl)-4-(4-sulfonylphenylamino)pyrido[4,3-*d*]pyrimidin-5(6*H*)-one; and~~

~~2-(4-(hydroxymethyl)piperidin-1-yl)-4-(4-morpholinophenylamino)pyrido[4,3-*d*]pyrimidin-5(6*H*)-one.~~